



**Areacor Therapeutics plc**  
("Areacor", the "Company" or the "Group")

**ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE**

- ***Ultra-concentrated, ultra-rapid acting insulin AT278, a promising candidate in the pursuit of next generation insulins to simplify and improve glycemic control***

**Cambridge, UK, 30 January 2023:** Areacor Therapeutics plc, a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that the American Diabetes Association journal, *Diabetes Care*, has published data from the Company's Phase I clinical trial of AT278, its ultra-concentrated (500 U/mL), ultra-rapid acting insulin product candidate.

The manuscript, titled 'Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People with Type 1 Diabetes', is now [available online](#).

In the Phase I clinical study in people with Type I diabetes, AT278 (500 U/mL) clearly demonstrated faster insulin absorption with an accelerated pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to gold-standard insulin NovoRapid® (100 U/mL) despite a 5-fold increase in concentration.

AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that has been designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. Currently, there are no concentrated (>200 U/mL) rapid acting insulin products on the market, and therefore, AT278 has the potential to be the first such product available to patients. It has the potential to enable more effective management of blood glucose levels to the increasing number of people with diabetes with high daily insulin requirements (>200 units/day) whilst maintaining the convenience and compliance benefits of being able to deliver these high insulin doses in a lower injection volume via a single injection. In addition, a truly rapid acting concentrated insulin is also a critical step towards the advancement and miniaturisation of the next generation of insulin delivery devices.

**Dr Eva Svehlikova, first author of the study, said:** "Publication of these data in a peer-reviewed journal supports the representation of AT278 as a promising candidate in the pursuit of next generation



insulin analogs designed to improve postprandial glyceemic control with its superior PK/PD profile as well as reducing the injection volume and/or number of daily injections for people with diabetes who have high daily insulin needs.”

**Sarah Howell, Chief Executive Officer of Arecor, said:** "Publication of the AT278 clinical trial in this prestigious journal highlights the significance of this clinical data and the need for our next generation insulins to bring improved treatment options to people living with diabetes to simplify and improve their blood glucose management. As a potential market disrupter, AT278 has the potential to become the gold standard insulin for the growing population of people with diabetes with high daily insulin needs as well as a critical enabler in the development of next generation miniaturised insulin delivery systems. With approximately 537 million people living with diabetes worldwide, of which approximately 56 million are insulin users, there has never been a greater need for improved treatment options.”

AT278 is also currently being investigated in a second Phase I trial in patients with Type 2 diabetes, to further explore the product’s potential to disrupt the market as the first concentrated, yet rapid acting, insulin. The study initiated earlier this month and is expected to complete within Q4 2023.

**-ENDS-**

**For more information, please contact:**

**Arecor Therapeutics plc**

Dr Sarah Howell, Chief Executive Officer

[www.arecor.com](http://www.arecor.com)

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: [info@arecor.com](mailto:info@arecor.com)

Mo Noonan, Communications

Tel: +44 (0) 7876 444977

Email: [mo.noonan@arecor.com](mailto:mo.noonan@arecor.com)

**Panmure Gordon (UK) Limited (NOMAD and Broker)**

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

**Consilium Strategic Communications**

Chris Gardner, David Daley, Angela Gray

Tel: +44 (0) 20 3709 5700

Email: [arecor@consilium-comms.com](mailto:arecor@consilium-comms.com)



## **Notes to Editors**

### **About Arecor**

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, [www.arecor.com](http://www.arecor.com)

### **About Diabetes Care**

*Diabetes Care* is a journal for the health care practitioner that is intended to increase knowledge, stimulate research, and promote better management of people with diabetes. For further details please see the website, <https://care.diabetesjournals.org/>